CR Bard Revenue and Competitors

New Providence, NJ USA

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • CR Bard's estimated annual revenue is currently $979.9M per year.(i)
  • CR Bard's estimated revenue per employee is $251,000

Employee Data

  • CR Bard has 3904 Employees.(i)
  • CR Bard grew their employee count by -5% last year.

CR Bard's People

NameTitleEmail/Phone
1
CEO/ChairmanReveal Email/Phone
2
Chairman and CEOReveal Email/Phone
3
CEO & PresidentReveal Email/Phone
4
Staff VP ManufacturingReveal Email/Phone
5
Corp Nat'l Accts VPReveal Email/Phone
6
Regional VPReveal Email/Phone
7
Staff VP ManufacturingReveal Email/Phone
8
Regional VPReveal Email/Phone
9
Regional VP Corporate AccountsReveal Email/Phone
10
Global VP - Supply ChainReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7.8M310%N/AN/A
#2
$15.1M60-3%N/AN/A
#3
$19.1M7625%N/AN/A
#4
$8M32-9%N/AN/A
#5
$4M1633%N/AN/A
#6
$315M12555%N/AN/A
#7
$380.3M15152%N/AN/A
#8
$0.5M2100%N/AN/A
#9
$10M403%N/AN/A
#10
$16.6M668%N/AN/A
Add Company

What Is CR Bard?

C. R. Bard (www.crbard.com), headquartered in Murray Hill, New Jersey, is a leading multinational developer, manufacturer, and marketer of health care products in the fields of vascular, urology, oncology, and surgical specialty products.

keywords:N/A

N/A

Total Funding

3904

Number of Employees

$979.9M

Revenue (est)

-5%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CR Bard News

2022-04-20 - COVID Illness Delays Bard, AngioDynamics Patent Trial In Del.

Law360 (April 22, 2022, 8:29 PM EDT) -- COVID-19 will delay trial in medical device maker C.R. Bard's patent suit against AngioDynamics after a member of...

2022-04-17 - 2nd Hernia Mesh Bellwether Trial Yields $255k Verdict

Last week, the 2nd bellwether test trial in the C.R. Bard hernia mesh MDL ended in a verdict for the plaintiffs awarding total damages of...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$22340M264061N/AN/A